Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.

Viruses - 1 Aug 2012

Miyamura Tatsuo, Kanda Tatsuo, Nakamoto Shingo, Wu Shuang, Jiang Xia, Arai Makoto, Fujiwara Keiichi, Imazeki Fumio, Yokosuka Osamu

Abstract excerpt

It has been reported that inosine triphosphatase (ITPA) gene variants protect against ribavirin-induced anemia in patients treated for chronic hepatitis C. IL28B variants also influence the treatment response of peginterferon plus ribavirin treatment in these patients. In the present study, we examined how ITPA and IL28B genotypes have clinical impacts on treatment-induced hematotoxicities and treatment response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Pyrophosphatases

Share to Ribavirin

Source

Open in PubMed Open full text

Identifiers

PMID: 23012624
DOI: 10.3390/v4081264
PMCID: PMC3446761

Genes

ITPA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.PMID 23012624Read ↗

Interleukin28B and inosine triphosphatase help to personalize hepatitis C treatment.Semantic proximity Read ↗

Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.Semantic proximity Read ↗

Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.Semantic proximity Read ↗

Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.Semantic proximity Read ↗

ITPA gene variant protects against anemia induced by pegylated interferon‐α and ribavirin therapy for Japanese patients with chronic hepatitis CSemantic proximity Read ↗

Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.Semantic proximity Read ↗

Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.Semantic proximity Read ↗

ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.Semantic proximity Read ↗

Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.Semantic proximity Read ↗

Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.Semantic proximity Read ↗

ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.Semantic proximity Read ↗

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.